Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

IF 12.9 1区医学 Q1 HEMATOLOGY

Blood Cancer Journal Pub Date : 2024-10-14 DOI:10.1038/s41408-024-01148-x

Jennifer K. Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman, Philip C. Caron, Kevin David, Zachary Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Paul Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, M. Lia Palomba, Ralphael Steiner, Robert Stuver, Pallawi Torka, Santosha Vardhana, Andrew D. Zelenetz, Heiko Schoder, Brandon Imber, Joachim Yahalom, Yanming Zhang, Pallavi Galera, Ahmet Dogan, Umut Aypar, Gilles Salles

引用次数: 0

Abstract Image

查看原文本刊更多论文

MYC、BCL2和/或BCL6重排的局限期高级别B细胞淋巴瘤：BCL2重排导致不良预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Journal ONCOLOGY-

CiteScore

16.70

自引率

2.30%

发文量

153

审稿时长

>12 weeks

期刊介绍： Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as: Preclinical studies of new compounds, especially those that provide mechanistic insights Clinical trials and observations Reviews related to new drugs and current management of hematologic malignancies Novel observations related to new mutations, molecular pathways, and tumor genomics Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.